TROPION-Lung01 Study Design and Baseline demographics
Background
• The emergence of platinum resistance in
recurrent OVC is inevitable; these patients
have a clear need for novel treatments¹
Mirvetuximab soravtansine-gynx received
accelerated approval from the FDA for the
treatment of patients with platinum-resistant,
FRa-positive OVC (ORR: 31.7%, median
DOR: 6.9 months)²
•
Expression of CDH6 is observed in -65-85%
of patients with OVC3,4
Raludotatug deruxtecan (R-DXd; DS-6000) is
a CDH6-directed ADC composed of three
parts: a humanized anti-CDH6 IgG1 mAb,
covalently linked to a topoisomerase I inhibitor
payload via a tetrapeptide-based cleavable
linker5
R-DXd was designed
with 7 key attributes
Humanized anti-CDH6
IgG1 mAba
Deruxtecan
H
H₂C-
ན་ཚིག་
NH
H
HỒ CH
Cleavable tetrapeptide-based linker
Topoisomerase I inhibitor payload
(DXd)
Payload mechanism of action: topoisomerase I inhibitor5.b
High potency of payload 5.b
High drug-to-antibody ratio=85,b
Payload with short systemic half-life 6.b.c
Tumor-selective cleavable linker5.b
Stable linker-payload 5.b
Bystander antitumor effect5,b
*Image is for illustrative purposes only; actual drug positions may vary. "The clinical relevance of these features is under investigation. *Based on animal data.
ADC, antibody-drug conjugate; CDH6, cadherin 8; DOR, duration of response; DXd, deruxtecan; FDA, United States Food and Drug Administration; FRa, folate receptor alpha; IgG1, immunoglobulin G1; mAb, monoclonal antibody; ORR, objective response rate; OVC, ovarian cancer.
1. Richardson DL, et al. JAMA Oncol. 2023;9:851-859; 2. ELAHERE™ (mirvetuximab soravtansine-gynx) prescribing information. Accessed September 1, 2023; 3. Bartolomé RA, et al. Mol Oncol. 2021;15:1849-1885;
4. Shintani D, et al. Gynecol Oncol. 2022:188(Suppl. 1):S118: 5. Suzuki H, et al. Ann Oncol. 2021:32(Suppl. 5):S381-5375; 8. Nakada T, et al. Chem Pham Bull (Tokyo). 2019:87:173–185.
Daiichi-Sankyo
53View entire presentation